The US pharmaceutical multinational Merck wants to bring the first Covid drug onto the market this year. Study results with the therapeutic molnupiravir are encouraging. The drug is said to reduce the risk of hospitalization or death by about half. In the competition with other pharmaceutical companies such as Pfizer and Roche, which are also researching coronavirus tablets, Merck is ahead by a nose.

A report published last week by the Harvard School of Public Health and King’s College Hospital in London shows that one generic molnupiravir costs $ 17.74 per therapy to make. This is while Merck is reportedly charging the US federal government more than $ 700 for a five-day molnupiravir regimen. In net terms, this corresponds to a 40-fold surcharge.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.